Investors
Learn about the device, its clinical phase, and how to invest in Zamenis Biotech Innovation.
The device
MABIS (Microwave Analyzer for Breast Imaging Scanning) is a portable medical device that uses ultra-wideband (UWB, 1–8 GHz) radar to analyze the dielectric contrast between tissues. An adaptable bra with 32 electromagnetic sensors conforms to each patient’s morphology, connected to a processing unit housed in a medical-case format.
An AI-assisted report identifies suspicious regions; the patient and medical staff access results through a remote digital platform.
Current phase
Phase 2 clinical trials at AUNA clinics, in collaboration with IREN-SUR hospital. MABIS is positioned as a complement to conventional methods, not a replacement.
Reference price
B2B and B2G model: equipment at USD 20,000 plus an USD 800 monthly subscription (maintenance, digital platform, updates and support).
Intellectual property
Utility model patent pending with INDECOPI, international PCT application filed, and MABIS trademark registered with INDECOPI (licensed by UCSP to Zamenis).
Market
Peru, Chile and Japan: the three markets where Zamenis projects MABIS's expansion.
Countries highlighted on the map as target markets: Peru, Chile, Japan.
Additional sectors in conversation: mining, manufacturing, agribusiness and transportation, via occupational health programs.
Invest in MABIS
Zamenis is raising capital to scale MABIS's clinical validation, advance its regulatory filing with DIGEMID, and prepare its entry into Chile and Japan. If your fund or institution evaluates early-stage medical devices, let's talk.
Let's talk
Write to us directly or fill out the form and we'll get in touch.